BioSpace News Archive

Agilent Companion Diagnostic Expands CE-IVD Mark for PD-L1 IHC 28-8 pharmDx to Include Esophageal Squamous Cell Carcinoma.

Agilent Technologies Inc. (NYSE: A) today announced CE-IVD marking in the European Union for its PD-L1 IHC 28-8 pharmDx immunohistochemical assay to extend the use of the test to patients diagnosed with muscle-invasive urothelial carcinoma (MIUC).

Agenus Inc., an immuno-oncology company with an extensive pipeline of therapeutics designed to activate immune response to cancers and infections, announced receipt of a $5M clinical milestone payment for AGEN2373.

Align Technology, Inc. a leading global medical device company that designs, manufactures, and sells the Invisalign system of clear aligners, iTero intraoral scanners, and exocad CAD/CAM software for digital orthodontics and restorative dentistry, announced that it will report first quarter 2022 financial results on Wednesday, April 27, 2022, after the close of market.

Allergan, an AbbVie (NYSE: ABBV) company, today announced that the Phase 3 VIRGO trial evaluating the safety and efficacy of investigational twice-daily administration of VUITY.

Multi-center Clinical Study Data on Anaconda Biomed’s Mechanical Thrombectomy System Published in Stroke.

BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted 19 newly-hired employees stock options to purchase an aggregate of 124,800 shares, and restricted stock units covering an aggregate of 47,400 shares, of BioCryst common stock.

Pharma Two B Ltd today announced that the efficacy and safety data from its recently completed Phase 3, randomized controlled trial of P2B001 in the management of early Parkinson’s disease is being presented today, April 5th.

Mind Medicine today announced the appointment of Francois Lilienthal, MD as Chief Commercial Officer.

Lakewood-Amedex, Inc. announced today that it has commenced its second Phase 2 study using Bisphosphocin Nu-3 antimicrobial in treating patients with diabetic foot ulcers (DFU).